SAN FRANCISCO and BERLIN, Feb. 08, 2023 (GLOBE NEWSWIRE) T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver
Investegate announcements from T-knife Therapeutics, T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial
The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial to evaluate TK-8001 in patients with MAGE-A1 positive solid tumors TK-8001 targets a MAGE-A1 epitope